Researcher Profile

Janice M. Mehnert, MD

Associate Professor of Medicine, Medical Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-6080
Email: mehnerja@cinj.rutgers.edu

Assistant: Pat Walker
(732) 235-6031
Email: walkerpa@cinj.rutgers.edu

Resident Member, Rutgers Cancer Institute of New Jersey


Research Program Alignment

Membership Type: Associate I


Research Interests

  • Melanoma
  • Developmental Therapeutics
  • Autophagy
  • Sonic Hedgehog
  • Transforming Growth Factor-Beta
  • Solid Tumors
  • Sarcoma

Selected Publications

Hill JM, Mehnert J, McCune SK and Brenneman DE. Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides; 23(10):1803-8, Oct. 2002.

Yip D, Le M, Chan J-L, Lee JH, Mehnert JM, Yudd A, Kempf JS, Shih WJ, Chen S, and Goydos JS. A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma. Clin Cancer Res Jun 1;15(11):3896-902, 2009.

Mehnert JM, McCarthy MM, Aziz SA, Flaherty KT, Camp RL, Rimm DL, Kluger HM. Quantitative Expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in Melanoma Tissue Microarrays. Human Pathology, 2010 Mar; 41(3):375-84, 2009.

Saraiya B, Chugh R, Karantza V, Mehnert J, Moss RA, Savkina N, Stein MN, Baker LH, Chenevert T, Poplin EA.  Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, Feb;30(1):258-65. 2010.

Khan A, Wall BA, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG. Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo. Clin Cancer Research, Apr 1;17(7):1807-14, 2011.

Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, and Karantza V. Rationally designed treatment for solid tumors with MAPK pathway activation: a Phase I study of paclitaxel and bortezomib in patients with advanced solid malignancies using an adaptive dose-finding approach. Mol Cancer Ther. Aug;10(8):1509-19, 2011.

The content for this Research Profile is maintained by Paul Novembre (novembre@cinj.rutgers.edu)